We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Emerging strategies to overcome resistance to third-generation EGFR inhibitors.
- Authors
Shi, Kunyu; Wang, Guan; Pei, Junping; Zhang, Jifa; Wang, Jiaxing; Ouyang, Liang; Wang, Yuxi; Li, Weimin
- Abstract
Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related to the inhibition of tumor cell proliferation, angiogenesis, invasion, metastasis, and apoptosis. Therefore, EGFR has become an important target for the treatment of cancer, including non-small cell lung cancer, head and neck cancer, breast cancer, glioma, cervical cancer, and bladder cancer. First- to third-generation EGFR inhibitors have shown considerable efficacy and have significantly improved disease prognosis. However, most patients develop drug resistance after treatment. The challenge of overcoming intrinsic and acquired resistance in primary and recurrent cancer mediated by EGFR mutations is thus driving the search for alternative strategies in the design of new therapeutic agents. In view of resistance to third-generation inhibitors, understanding the intricate mechanisms of resistance will offer insight for the development of more advanced targeted therapies. In this review, we discuss the molecular mechanisms of resistance to third-generation EGFR inhibitors and review recent strategies for overcoming resistance, new challenges, and future development directions.
- Subjects
EPIDERMAL growth factor receptors; NON-small-cell lung carcinoma; HEAD &; neck cancer
- Publication
Journal of Hematology & Oncology, 2022, Vol 15, Issue 1, p1
- ISSN
1756-8722
- Publication type
Article
- DOI
10.1186/s13045-022-01311-6